Larimar Therapeutics (LRMR) Net Cash Flow Growth (3y) (2016 - 2025)
Powered by 
Analysis
Larimar Therapeutics (LRMR) Net Cash Flow Growth (3y) (2016 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -10.13% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -98.96% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -8.34% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 36.60% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -35.85% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 67.39% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -96.44% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 52.78% |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 58.40% |
| Mar 31, 2025 | -17.09% |
| Dec 31, 2024 | -22.45% |
| Sep 30, 2024 | 28.97% |
| Jun 30, 2024 | -123.89% |
| Mar 31, 2024 | 151.99% |
| Dec 31, 2023 | 28.71% |
| Sep 30, 2023 | -69.79% |
| Jun 30, 2023 | -29.11% |
| Mar 31, 2023 | 786.32% |
| Dec 31, 2022 | -135.99% |
| Sep 30, 2022 | -61.91% |
| Jun 30, 2022 | -42.18% |
| Mar 31, 2022 | 13.33% |
| Dec 31, 2021 | -32.78% |
| Sep 30, 2021 | -84.89% |
| Jun 30, 2021 | 54.56% |
| Mar 31, 2021 | -47.39% |
| Dec 31, 2020 | -52.35% |
| Sep 30, 2020 | 3.21% |